Published Date: August 3, 2023

Full Text Article

A PSD-95 peptidomimetic mitigates neurological deficits in a mouse model of Angelman syndrome

Authors: Kara A Lau, Xin Yang, Mengia S Rioult-Pedotti, Stephen Tang, Mark Appleman, Jianan Zhang, Yuyang Tian, Caitlin Marino, Mudi Yao, Qin Jiang, Ayumi C Tsuda, Yu-Wen Alvin Huang, Cong Cao, John Marshall

Prog Neurobiol. 2023 Nov;230:102513. doi: 10.1016/j.pneurobio.2023.102513. Epub 2023 Aug 1.


Angelman Syndrome (AS) is a severe cognitive disorder caused by loss of neuronal expression of the E3 ubiquitin ligase UBE3A. In an AS mouse model, we previously reported a deficit in brain-derived neurotrophic factor (BDNF) signaling, and set out to develop a therapeutic that would restore normal signaling. We demonstrate that CN2097, a peptidomimetic compound that binds postsynaptic density protein-95 (PSD-95), a TrkB associated scaffolding protein, mitigates deficits in PLC-CaMKII and PI3K/mTOR pathways to restore synaptic plasticity and learning. Administration of CN2097 facilitated long-term potentiation (LTP) and corrected paired-pulse ratio. As the BDNF-mTORC1 pathway is critical for inhibition of autophagy, we investigated whether autophagy was disrupted in AS mice. We found aberrantly high autophagic activity attributable to a concomitant decrease in mTORC1 signaling, resulting in decreased levels of synaptic proteins, including Synapsin-1 and Shank3. CN2097 increased mTORC1 activity to normalize autophagy and restore hippocampal synaptic protein levels. Importantly, treatment mitigated cognitive and motor dysfunction. These findings support the use of neurotrophic therapeutics as a valuable approach for treating AS pathology.

PMID: 37536482DOI: 10.1016/j.pneurobio.2023.102513